Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Alexander M. Spence, Mitchel S. Berger, Robert B. Livingston, Francis Ali-Osman, Brian Griffin

Research output: Contribution to journalArticle

44 Scopus citations


Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalJournal of Neuro-Oncology
Issue number2
StatePublished - Feb 1 1992



  • astrocytoma
  • brain tumors
  • chemotherapy
  • cisplatin
  • glioblastoma
  • malignant glioma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this